Islet transplantation: An update

Diabetes/Metabolism Reviews

Volumn 12, Issue 2, 1996, Pages 137-150

  Sutherland, David E R ^a   Gores, Paul F ^a   Hering, Bernhard J ^a   Wahoff, David ^a   McKeehen, Debra A ^a   Gruessner, Rainer W G ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; C PEPTIDE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ALLOGRAFT; AUTOIMMUNITY; CELL COUNT; GRAFT REJECTION; HUMAN; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ADULT; ANIMALS; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; PANCREATECTOMY; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029745147     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199607)12:2<137::AID-DMR159>3.0.CO;2-1     Document Type: Review

References (120)

1. London NJM, Robertson GSM, Chadwick DR, Johnson PRV, James RFL, and Bell PRF: Human pancreatic islet isolation and transplantation. Clin Transplant 8: 421-459, 1994.
2. Federlin K, Bretzel RG, Hering B, Geier C, Scultz AO, Vietke R, and Watz B: International Islet Transplant Newsletter 5: 1-27, 1995.
3. Federlin KF, Bretzel RG, and Hering BJ: International islet transplant registry. International Islet Transplant Newsletter 4: 1-20, 1994.
4. Hering BJ, Schultz AO, Geier C, Bretzel RG, and Federlin K: Islet Transplant Registry Newsletter No. 6, 5: 1-28, 1995.
5. Ricordi C, Tzakis AG, Carroll PB, Zeng Y, Rodrigues-Rilo HL, Alejandro R, Shapiro R, Fung JJ, Demetris AJ, Mintz DH, and Starzl TE: Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 53: 407-442, 1992.
6. Tzakis AG, Ricordi C, Alejandro R, Zeng Y, Fung JJ, Todo S, Demetris AJ, Mintz DH, and Starzl TE: Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 336: 402-405, 1990.
7. Socci C, Mazzaferro V, Regalia E, Bertuzzi F, Andreola S, Colella G, Maffi P, Mirenda V, Damascelli B, Magistretti P, Doci R, Bozzetti F, Di Carlo V, Gennari L, and Pozza G: Insulin independence after islet-liver transplantation for metastatic neuroendocrine pancreatic tumor. Transplant Proc 26: 577-578, 1994.
8. Engemann R, Hering BJ, Timmermann W, Gassel HJ, Meyer D, Schang T, Brandhorst H, Brandhorst D, Bretzel RG, Federlin K, and Thiede A: Kombinierte Leber-Insel-Transplantation nach Oberbauchexenteration bei Papillencarcinom. Chirurg 66: 371-376, 1995.
9. Kenyon NS, Ricordi C, and Mintz DL: Islet cell transplantation, in press.
10. Wahoff DC, Papalois BE, Najarian JS, Kendall DM, Farney AC, and Leone JP: Autologous islet transplantation to prevent diabetes after pancreatic resection. Ann Surg 222: 562-575, discussion 575-579, 1995.
11. Ricordi C, Gray DWR, and Hering BJ: Islet isolation assessment in man and large animals. Acta Diabetol Lat 27: 185, 1990.
12. Squifflet JP, Sutherland DER, Morrow CE, Monda L, Field MJ, and Najarian JS: The postoperative course and quantitative aspects of rat islet and segmental pancreas isografts. J Surg Res 36: 578-587, 1984.
13. Squifflet JP, Sutherland DER, Morrow CE, Florack G, Field MJ, and Najarian JS: Comparison of rejection of intraportal islet versus immediately vascularized segmental pancreatic allografts in rats in relation to beta cell mass engrafted. Transplant Proc 15: 1344-1346, 1983.
14. Munn SR, Kaufman DB, Meloche RM, Field MJ, and Sutherland DER: Weight-corrected islet counts are predictive of outcome in the canine intrahepatic islet autograft model. Diabetes Res 9: 121-124, 1988.
15. Kaufman DB, Morel P, Field MJ, Munn SR, and Sutherland DER: Purified canine islet autografts: functional outcome as influenced by islet number and implantation site. Transplantation 50: 385-391, 1990.
16. Warnock GL, and Rajotte RV: Critical mass of purified islets that induce normoglycemia after implantation into dogs. Diabetes 37: 467, 1988.
17. Kaufman DB, Morel P, Condie RM, Field MJ, Rooney M, Tzardis PJ, Stock PG, and Sutherland DER: Beneficial and detrimental effects of RBC-absorbed antilymphocyte globulin and prednisone on purified canine islet autograft and allograft funciton. Transplantation 51: 37-42, 1991.
18. Gray DWR, Warnock GL, Sutton R, Peters M, McShane P, and Morris PJ: Successful autotransplantation of isolated islets of Langerhans in the cynomolgus monkey. Br J Surg 73: 850, 1986.
19. Stegall MD, Chabot J, Weber C, Reemtsma K, and Hardy MA: Pancreatic islet transplantation in cynomolgus monkeys: initial studies and evidence that cyclosporine impairs glucose tolerance in normal monkeys. Transplantation 48: 944, 1989.
20. Farney AC, Najarian JS, Nakhleh RE, Lloveras G, Field MJ, Gores PF, and Sutherland DER: Autotransplantation of dispersed pancreatic islet tissue combined with total or near-total pancreatectomy for treatment of chronic pancreatitis. Surgery 110: 427-439, 1991.
21. Pyzdrowski KL, Kendall DM, Halter JB, Nakhleh RE, Sutherland DER, and Robertson RP: Preserved insulin secretion and insulin independence in recipients of islet autografts. N Engl J Med 327: 220-226, 1992.
22. Hellman B: The frequency distribution of the number and volume of the islets of Langerhans in man. Acta Soc Med Upsalien 64: 432, 1959.
23. Saito K, Iwama N, and Takahashi T: Morphometrical analysis on topographical difference in size distribution, number and volume of islets in the human pancreas. Tohoku J Exp Med 124: 177, 1978.
24. Ricordi C, Lacy PE, and Scharp DW: Automated islet isolation from human pancreas. Diabetes 38(suppl): 20-22, 1989.
25. Cavanagh TJ, Fetterhoff TJ, Lonergan SC, Dwulet FE, Gill JF, and McCarthy RC: Collagenase selection. In Pancreatic Islet Transplantation, Vol I, Lanza RP, and Chick WL (Eds). RG Landes, Austin, 1994, pp. 39-51.
26. Benhamou PY, Watt PC, Mullen Y, Ingles S, Watanabe Y, Nomura Y, Hober C, Miyamoto M, Kenmochi T, Passaro EP, Zinner MJ, and Brunicardi FC: Human islet isolation in 104 consecutive cases. Transplantation 57: 1804-1810, 1994.
27. Gores PF, and Sutherland DER: Pancreatic islet transplantation: is purification necessary? Am J Surg 166: 32767-32760, 1993.
28. Mehigan DG, Bell WR, Zuidema GD, Eggleston JC, and Cameron JL: Disseminated intravascular coagulation and portal hypertension following pancreatic islet autotransplantation. Ann Surg 191: 287-293, 1979.
29. Toledo-Pereyra LH, Rowlett AL, Cain W, Rosenberg JC, Gordon DA, and MacKenzie GH: Hepatic infarction following intraportal islet cell autotransplantation after near-total pancreatectomy. Transplantation 38: 88-89, 1984.
30. Farney AC, Najarian JS, Nakhleh RE, Field MJ, Morel P, Lloveras JJ, Gores PF, and Sutherland DER: Long-term function of islet autotransplants. Transplant Proc 24: 969-971, 1992.
31. Gores PF, Najarian JS, Stephanian E, Lloveras JJ, Kelley SL, and Sutherland DER: Transplantation of unpurified islets from single donors with 15-deoxyspergualin. Transplant Proc 26: 574-575, 1994.
32. Wahoff DC, Sutherland DER, Hower CD, Lloveras JJ, and Gores PF: Free intraperitoneal islet autografts in pancreatectomized dogs: impact of islet purity and posttransplantation exogenous insulin. Surgery 116: 742-750, 1994.
33. Gray DWR, Sutton R, McShane P, Peters M, and Morris PJ: Exocrine contamination impairs implantation of pancreatic islets transplanted beneath the kidney capsule. J Surg Res 45: 432, 1988.
34. Mirkovitch V, and Campiche M: Intrasplenic autotransplantation of canine pancreatic tissues, maintenance of normoglycemia after total pancreatectomy. Eur Surg Res 9: 173-190, 1977.
35. Mieny CJ, and Smit JA: Autotransplantation of pancreatic tissue in totally pancreatectomized baboons. S Afr J Surg 16: 19-21, 1978.
36. Scopsi L, Andreola S, Socci C, Bertuzi F, Di Carlo V, Pozza G, Rilke F, Gennari L, Colella G, Regalia E, and Mazzaferro V: Immunocytochemical detection and characterization of intrahepatic human pancreatic islets after combined liverislet allotransplantation. Cell Transplant 3: 499-508, 1994.
37. Gores PF, Mayoral JL, Field MJ, and Sutherland DER: Comparison of the immunogenicity of purified and unpurified murine islet allografts. Transplantation 41: 529, 1986.
38. Gotoh M, Maki T, Satomi S, Porter J, and Monaco AP: Immunological characteristics of purified pancreatic islet grafts. Transplantation 42: 387, 1986.
39. Stock PG, Ascher NL, Chen S, Field MJ, Bach FH, and Sutherland DER: Evidence for direct and indirect pathways in the generation of the alloimmune response against pancreatic islets. Transplant Proc 52: 704, 1991.
40. Ulrichs K, and Muller-Ruchholtz W: Mixed lymphocyte islet culture (MLIC) and its use in manipulation of human islet alloimmunogenicity. Horm Metab Res 25: 123, 1990 (Abstract).
41. Stock PG, Ascher NL, Chen S, Field MJ, Bach FH, and Sutherland DER: Evidence for direct and indirect pathways in the generation of the alloimmune response against pancreatic islets. Transplantation 52: 704-709, 1991.
42. Pipeleers DG, Pipeleers-Marichal M, Vanbrabandt B, and Duys S: Transplantation of purified islet cells in diabetic rats. II. Immunogenicity of allografted islet B-cells. Diabetes 40: 920-930, 1991.
43. Pipeleers-Marichal M, Zhi-Dong L, Teng M, and Pipeleers DG: Transplantation of purified islet cells in diabetic rats. Diabetes 40: 931-938, 1991.
44. Robertson GSM, Chadwick DR, Contractor H, James RFL, and London NJM: The optimization of large scale density gradient human islet isolation. Acta Diabetol 1993.
45. London NJM, Robertson GSM, and Chadwick DR: Purification of human pancreatic islets by large scale continuous-density gradient centrifugation. Horm Metab Res 25: 61, 1993 (Abstract).
46. London NJM, Johnson PRV, Robertson GSM, Chadwick DR, and White S: Approaches to islet purification. In Pancreatic Islet Transplantation Vol I, Lanza RP, and Chick WL (Eds). RG Landes, Austin, 1994, pp. 25-38.
47. Gores PF, Gillingham KJ, Dunn DL, Moudry-Munns KC, Najarian JS, and Sutherland DER: Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience. Ann Surg 215: 217-230, 1992.
48. Brayman KL, Gillingham KJ, Moudry-Munns KC, Gores PF, Dunn DL, and Sutherland DER: A multivariate analysis of HLA mismatching in solitary pancreas transplantation. Hum Immunol 32(Suppl 1): 54, 1991.
49. Alejandro R, Latif Z, Polonsky KS, Shienvold FL, Civantos F, and Mint DH: Natural history of multiple intrahepatic canine islet allografts during and following administration of cyclosporine. Transplantation 45: 1036, 1988.
50. Gotoh M, Porter J, Kanai T, Monaco AP, and Maki T: Multiple donor allotransplantation: a new approach to pancreatic islet transplantation. Transplantation 45: 1008, 1988.
51. Keller RJ, Eisenbarth GS, and Jackson RA: Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341: 927-928, 1993.
52. Faustman D, and Coe C: Prevention of xenograft rejection by masking donor HLA class i antigens. Science 252: 1700-1702, 1991.
53. Cassidy LE, and Newgard CB: Glucose stimulated insulin secretion in cell lines. Diabetes Nutr Metab 7: 189-195, 1994.
54. Kaufman DB, Platt J, Rabe FL, Dunn DL, Bach FH, and Sutherland DER: Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lympho- cytes in primary nonfunction and classic rejection of islet allografts. J Exp Med 172: 291, 1990.
55. Kaufman DB, Field MJ, Gruber SA, Farney AC, Stephanian E, Gores PF, and Sutherland DER: Extended functional survival of murine islet allograft with 15-deoxyspergualin. Transplant Proc 24: 1045-1047, 1992.
56. Stevens RB, Ansite JD, and Lokeh A: The role of nitric oxide in the pathogenesis of early pancreatic islet dysfunction during rat and human intraportal islet transplantation. Transplant Proc 26: 692-690, 1994.
57. Malaisse WJ, Malaisse-Lagae F, Sener A, and Pipeleers DG: Determinants of the selective toxicity of alloxan to the pancreatic B cell. Proc Natl Acad Sci USA 79: 927-930, 1982.
58. Marklund SL: Regulation by cytokines of extracellular superoxide dismutase and other superoxide dismutase isoenzymes in fibroblasts. J Biol Chem 267: 6696-6701, 1992.
59. Nathan CF, and Tsunawaki S: Secretion of toxic oxygen products by macrophages: regulatory cytokines and their effects on the oxidase. Ciba Found Symp 118: 211-230, 1986.
60. Stevens BR, Ansite JD, Mills CD, Lokeh A, Rossini TJ, Saxena M, Brown R, and Sutherland DER: Nitric oxide mediates early dysfunction of rat and mouse islets following transplantation. Transplantation, in press.
61. Sandler S, Bendtzen K, Hakan-Borg LA, Eizirik DL, Strandell E, and Welsh N: Studies on the mechanisms causing inhibition of insulin secretion in rat pancreatic islets exposed to human interleukin-1B indicate a perturbation in the mitochondrial function. Endocrinology 124: 292-1501, 1989.
62. Sumoski W, Baquerizo H, and Rabinovitch A: Oxygen free radical scavengers protect rat islet cells from damage by cytokines. Diabetologia 792: 796, 1989.
63. Arai KE, Lee F, Mijajima A, Myatake S, Arai N, and Yokota T: Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 59: 783-836, 1990.
64. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, and Svenson M: Cytotoxicity of human p17 interleukin-1 for pancreatic islets of Langerhans. Science 232: 1545-1547, 1986.
65. Ling Z, Veld PA, and Pipeleers DG: Interaction of interleukin-1 with islet B-cells: distinction between indirect, aspecifcic cytotoxicity and direct, specific functional suppression. Diabetes 42: 56-65, 1993.
66. Campbell IL, Iscaro A, and Harrison LC: IFN-g and tumor necrosis factor-a: cytotoxicity to murine islets of Langerhans. J Immunol 21: 2325-2329, 1988.
67. Mandrup-Poulsen T, Bendtzen K, Dinarello CA, and Nerup J: Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic B-cells cytotoxicity. J Immunol 139: 4077-4082, 1987.
68. Nathan CF: Secretory products of macrophages. J Clin Invest 79: 319, 1987.
69. Walter PK, Dickneite G, and Schorlemmer HU: Prolongation of graft survival in allogeneic islet transplantation by 15-deoxyspergualin in the rat. Diabetologia 30: 38, 1987 (Abstract).
70. Farney AC, Xenos ES, and Sutherland DER: Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant Proc 25: 865, 1993.
71. Sutherland DER, Sibley RK, Xu XZ, Michael AF, Srikanta S, Taub F, Najarian JS, and Goetz FC: Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Phys 97: 80-87, 1984.
72. Gruessner RWG, and Sutherland DER: Clinical diagnosis in pancreas allograft rejection. In Solid Organ Transplant Rejection: Mechanisms, Pathology and Diagnosis, Solez K, Racusen LC, and Billingham M (Eds). Marcel Dekker, New York, 1996, pp. 455-499.
73. Gores PF, Najarian JS, Stephanian E, Lloveras JJ, Kelley SL, and Sutherland DER: Insulin independence in type I diabetes after transplantation of unpurified islets from a single donor using 15-deoxyspergualin. Lancet 341: 19-21, 1993.
74. London, NJM, Johnson PRV, Robertson GSM, Chadwick DR, and White S: Frequency of kidney rejection in diabetic patients undergoing simultaneous kidney and pancreatic islet cell transplantation. Transplantation 55: 761, 1993.
75. Wahoff DC, Najarian JS, Sutherland DER, and Gores PF: Effect of pancreatic islet allografts on kidney allograft rejection incidence in simultaneous islet/kidney and islet after kidney recipients. Transplant Proc 26: 576-570, 1994.
76. Simeonovic CJ, Bowen KM, Kotlausk I, and Lafferty KJ: Modulation of tissue immunogenicity by organ culture: comparison of adult islets and fetal pancreas. Transplantation 30: 174, 1980.
77. Faustman D, Hauptfeld V, Lacy PE, and Davie JM: Prolongation of murine allograft survival by pretreatment of islets with antibody directed to la determinants. Proc Natl Acad Sci USA 78: 5156, 1981.
78. Al-Abdullah IH, Kumar AM, Al-Adnani MS, and Abouna GM: Prolongation of allograft survival in diabetic rats treated with cyclosporine by deoxyguanosine pretreatment of pancreatic islets of Langerhans. Transplantation 51: 967, 1991.
79. Lau H, Reemtsma K, and Hardy MA: Prolongation of rat islet allograft survival by direct ultraviolet irradiation of the graft. Science 223: 607, 1984.
80. Gores PF, Sutherland DER, Platt J, and Bach FH: Depletion of donor Ia+ cells before transplantation does not prolong islet allograft survival. J Immunol 137: 282, 1986.
81. Piehlmeier W, Bullinger M, Kirchberger I, König A, Scheuer R, Illner WD, Land W, and Landgraf R: Prospective study of the quality of life in type I diabetic patients before and after organ transplantation. Transplant Proc 26: 522-523, 1994.
82. Kenyon NS, Strasser S, and Alejandro R: Ultraviolet light immunomodulation of canine islets for prolongation of allograft survival. Diabetes 39: 305-s, 1990.
83. Posselt AM, Barker CF, Tomaszewski JE, Marmann JF, Choti MA, and Naji H: Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science 249: 1293, 1990.
84. Posselt AM, Odorico JS, Barker CF, and Naji A: Promotion of pancreatic islet allograft survival by intrathymic transplantation of bone marrow. Diabetes 41: 771, 1992.
85. Soon-Shiong P, Heintz RE, Merideth N, Yao QX, Yao Z, Zheng T, Murphy M, Moloney MK, Schmehl M, and Harris H: Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 343: 950-951, 1994.
86. Sutherland DER, Goetz FC, and Sibley RK: Recurrence of disease in pancreas transplants. Diabetes 38: 85-87, 1989.
87. Sutherland DER, and Sibley RK: Recurrence of Disease in Pancreas Transplants. Elsevier Science, Amsterdam, 1988, pp. 60-66.
88. Boudreaux JP, McHugh LE, and Canafax DM: The impact of cyclosporine and combination immunosuppression on the incidence of post-transplant diabetes in renal allograft recipients. Transplantation 44: 376, 1987.
89. Teuscher AU, Seaquist ER, and Robertson RP: Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes 43: 593-598, 1994.
90. Christiansen E, Andersen HB, Rasmussen K, Christensen NJ, Olgaard K, Kirkegaard P, Tronier B, Volund A, Damsbo P, Burcharth F, and Madsbad S: Pancreatic B-cell function and glucose metabolism in human segmental pancreas and kidney transplantation. Am J Physiol 264: E441-E449, 1993.
91. Stock PG, Sutherland DER, Dunning M, Field MJ, Casanova D, Prieto M, and Najarian JS: Detrimental effects of triple immunosuppressive therapy on pancreatic islet allografts in canine model. Diabetes 38(Suppl 1): 308, 1989 (Abstract).
92. Zeng Y, Ricordi C, and Lendoire J: The effect of prednisone on pancreatic islet autografts in dogs. Surgery 113: 98, 1993.
93. Kahn CR, Goldfine ID, Neville DM, and Demeyts P: Alteration in insulin binding induced by changer in vivo in the levels of glucocorticoids and growth hormone. Endocrinology 103: 1054, 1987.
94. Cigolini M and Smith U: Human adipose tissue in culture VIII. Studies on the insulin-antagonistic effect of glucocorticoids. Metabolism 28: 502: 1979.
95. Gagano G, Cavallo-Perin P, and Cassader M: An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 72: 1814, 1983.
96. Cahill, G: Action of adrenal cortical steroids on carbohydrate metabolism. In The Human Adrenal Cortex, Christy N (Ed). Harper & Row, New York, 1971, p. 205.
97. Randle PJ, Garland PB, Maler CN, and Newsholme EA: The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet i: 785, 1963.
98. Edstrand AV, Eriksson JG, Gronhagen-Riska C, Ahonen PJ, and Groop LF: Insulin resistance and insulin deficiency in the pathogenesis of posttransplant diabetes in man. Transplantation 53: 563, 1992.
99. International Pancreas Transplant Regisry: Newsletter 8(No. 1): Supplemental, Annual Report of IPTR, June 15, 1995.
100. Rilo HLR, Carroll PB, Zeng Y, Fontes P, Demetris J, and Ricordi C: Acceleration of chronic failure of intrahepatic canine islet autografts by a short course of prednisone. Transplantation 57: 181-187, 1994.
101. Merrel RC, Mahoney ME, Basadonna GP, Cobb LF, and Maeda M: Failure of canine islet allografts and autografts with cyclosporine. Surgery 98: 324, 1985.
102. Gores PF, Boudreaux JP, Hesse UJ, Najarian JS, and Sutherland DER: Canine islet autografts with and without administration of cylcosporine. Surgery 101: 557, 1987.
103. Andersson A, Borg H, Hallberg A, Hellerstrom C, Sandler S, and Schnell A: Long-term effects of cyclosporin A on cultured mouse pancreatic islets. Diabetologia 27: 66, 1984.
104. Martin F, and Bedoya FJ: Short-term effects of cyclosporine on secretagogue-induced insulin release by isolated islets. Transplantation 50: 551, 1990.
105. Königsrainer A, Föger BH, Miesenbock G, Patsch JR, and Margreiter R: Pancreas transplantation with systemic endocrine drainage leads to improvement in lipid metabolism. Transplant Proc 26: 501-502, 1994.
106. Gruessner RWG, Sutherland DER, Drangstveit MB, Troppmann C, and Gruessner AC: The use of FK506 in pancreas transplantation. Transplant Int, in press.
107. Ericzon BG, Wijnen RM, Kubota K, Kootstra G, and Groth CG: FK 506-induced impairment of glucose metabolism in the primate: studies in pancreatic transplant recipients and in nontransplanted animals. Transplantation 54: 615-620, 1992.
108. Gores, PF, and Sutherland DER. Immunosuppression for islet transplantation. In Pancreatic Islet Transplantation, Vol II, Lanza RP, and Chick WL (Eds). RG Landes, Austin, 1994, pp. 63-74.
109. Morris RP: Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 6: 39-87, 1992.
110. Gruessner RWG, Burke GW, Stratta R, Sollinger H, Benedetti E, Marsh C, Stock P, Boudreaux JP, Martin M, and Drangstveit MB: Multicenter analysis of the first experience with FK 506 for induction and rescue therapy after pancreas transplantation. Transplantation 61: 261-273, 1996.
111. Xenos ES, Casanova D, Sutherland DER, Farney AC, Lloveras JJ, and Gores PF: The in vivo and in vitro effect of 15-deoxyspergualin on pancreatic islet function. Transplantation 56: 24, 1993.
112. Platz KP, Sollinger HW, Mullett DA, Eckhoff DE, Eugui EM, and Allison AC: RS-6243: A new potent immunosuppressive agent. Transplantation 51: 27-31, 1991.
113. Sandberg SS, and Anderson A: Exposure of rat pancreatic islets to RS-6243 inhibits B-cell function. International Congress on Pancreas and Islet Transplantation, Amsterdam, 1993 (Abstract).
114. Yakimets WJ, Lakey JRT, Yatscoff RW, Katyal D, Ao Z, Finegood DT, Rajotte RV, and Kneteman NM: Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Transplantation 56: 1293-1298, 1993.
115. Granger DK, Matas AJ, Jenkins MK, Moss AA, Chen SC, and Almond PS: Prolonged survival without posttransplantation immunosuppression in a large animal model. Surgery 116: 419-425, 1994.
116. Mieles L, Gordon RD, Mintz DH, Toussaint RM, Imventarza O, and Starzl TE: Glycaemia and insulin need following FK506 rescue therapy in liver recipients. Transplant Proc 23: 949, 1991.
117. Fabrega AJ, Cohan J, Meslar P, and Pollak R: Effects of steroid withdrawal on long-term renal allograft recipients with posttransplantation diabetes mellitus. Surgery 116: 792-797, 1994.
118. Warnock GL, and Rajotte RV: Human pancreatic islet transplantation. Transplant Rev 6: 195-208, 1992.
119. Ricordi C, Hering BJ, London NJM, Rajotte RV, Gray DWR, Sutherland DER, Socci C, Alejandro R, Carroll PB, Bretzel RG, and Scharp DW: Islet Isolation Assessment. RG Landes, Austin, 1992, pp. 132-142.
120. Sutherland DER, Morel P, and Gruessner RWG: Transplantation of two diabetic patients with one divided cadaver donor pancreas. Transplant Proc 22: 585, 1990.